Shots:

• The approval is based on P-III IMpower150 study results assessing Tecentriq + CT (paclitaxel & carboplatin) + Avastin (bevacizumab) (w or w/o) in 1202 patients in ratio (1:1:1) with Stage IV or recurrent mNon-sq NSCLC not treated with CT
• P-III IMpower150 study results (Tecentriq + carboplatin and paclitaxel- Tecentriq +Avastin + carboplatin & paclitaxel- Avastin + carboplatin & paclitaxel): OS (19.2 vs 14.7 mos.); reduced risk of disease worsening or death 29%- ORR (55% vs 42%); CR 4%; PR 51%; mDOR (10.8 vs 6.5 mos.)
• Tecentriq is a mAb used for binding PD-L1 protein- while blocking interaction with PD-1 and B7.1 receptors

  Ref: Genentech | Image: Nature